Effect of YM-254890, a specific Gαq/11 inhibitor, on experimental peripheral arterial disease in rats

European Journal of Pharmacology

Volumn 536, Issue 1-2, 2006, Pages 154-161

  Uemura, Toshio ^a   Takamatsu, Hajime ^a   Kawasaki, Tomihisa ^a   Taniguchi, Masatoshi ^a   Yamamoto, Eisaku ^a   Tomura, Yuichi ^a   Uchida, Wataru ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

G q 11 inhibitor; Local administration; Peripheral arterial disease; Platelet aggregation; Vasodilation

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BERAPROST; CLOPIDOGREL; ENDOTHELIN 1; LAURIC ACID; PHENYLEPHRINE; PROSTAGLANDIN E1; SEROTONIN; UNCLASSIFIED DRUG; YM 254890;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTERIAL PRESSURE; ARTERY DISEASE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN BLOOD FLOW; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

ANIMALS; AORTA; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DERMIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART RATE; HINDLIMB; LAURIC ACIDS; MALE; PEPTIDES, CYCLIC; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TICLOPIDINE; VASODILATION; VASODILATOR AGENTS;

EID: 33645818728     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.048     Document Type: Article

References (25)

1. Ashida S., Ishihara M., Ogawa H., and Abiko Y. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats. Thromb. Res. 18 (1980) 55-67
2. Barradas M.A., Gill D.S., Fonseca V.A., Mikhailidis D.P., and Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur. J. Clin. Investig. 18 (1988) 399-404
3. Carlson L.A., and Eriksson I. Femoral-artery infusion of prostaglandin E1 in severe peripheral vascular disease. Lancet 1 (1973) 155-156
4. Dashwood M.R., Jagroop I.A., Gorog D.A., and Bagger J.P. A potential role for endothelin-1 in peripheral vascular disease. J. Cardiovasc. Pharmacol. 36 5 Suppl. 1 (2000) S93-S94
5. De Cree J., Roels V., and Verhaegen H. Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist. Drugs 36 Suppl. 1 (1988) 87-91
6. Goto J., Araki H., Otomo S., and Aihara H. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats. Drugs Exp. Clin. Res. 12 (1986) 917-921
7. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344 (2001) 1608-1621
8. q/11 inhibitor, in a rat model of arterial thrombosis. Thromb. Haemost. 90 (2003) 406-413
9. q/11 inhibitor, on thrombosis and neointima formation in mice. Thromb. Haemost. 94 (2005) 184-192
10. q-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 40 (2002) 660-666
11. Kihara H., Hirose K., Koganei H., Sasaki N., Yamamoto H., Kimura A., Nishimori T., Shoji M., and Yoshimoto R. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J. Cardiovasc. Pharmacol. 35 (2000) 523-530
12. Lievre M., Morand S., Besse B., Fiessinger J.N., and Boissel J.P. Oral Beraprost sodium, a prostaglandin I(2) Analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 102 (2000) 426-431
13. Matsagas M.I., Geroulakos G., and Mikhailidis D.P. The role of platelets in peripheral arterial disease: therapeutic implications. Ann. Vasc. Surg. 16 (2002) 246-258
14. Motoyama Y., Sakata Y., Seki J., Dohi M., and Yoshida K. Effect of TFC-612, a 7-thia prostaglandin E1 derivative, on a peripheral arterial occlusive disease model in rats. Prostaglandins 49 (1995) 175-182
15. Murai T., Muraoka K., Saga K., Sakai A., Sato N., Amemiya K., Yajima M., Murata T., Umetsu T., and Nishio S. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits. Arzneim. Forsch. 39 (1989) 856-859
16. Nishio S., Matsuura H., Kanai N., Fukatsu Y., Hirano T., Nishikawa N., Kameoka K., and Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol. 47 (1988) 1-10
17. Nishio S., Yamada N., Endoh T., Isogaya M., Fukatsu Y., Nishimura S., Kanai N., and Umetsu T. Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli. Arzneim. Forsch. 39 (1989) 1229-1234
18. Ogawa T., Sugidachi A., Tanaka N., Fujimoto K., and Asai F. Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease. Vasc. Pharmacol. 41 (2004) 7-13
19. Sugidachi A., Asai F., Ogawa T., Inoue T., and Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129 (2000) 1439-1446
20. q/11 inhibitor. J. Biol. Chem. 279 (2004) 47438-47445
21. Taniguchi M., Nagai K., Arao N., Kawasaki T., Saito T., Moritani Y., Takasaki J., Hayashi K., Fujita S., Suzuki K., and Tsukamoto S. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J. Antibiot. 15 (2003) 358-363
22. q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Br. J. Pharmacol..
23. Umetsu T., Murata T., and Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneim. Forsch. Drug Res. 39 (1989) 68-73
24. Winer B.J., Brown D.R., and Michels K.M. Statistical Principles in Experimental Design. 3rd ed. (1991), McGraw-Hill, New York, NY
25. + channel opener KRN4884 on peripheral occlusive arterial disease in rats. Gen. Pharmacol. 31 (1998) 59-62